TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis
Authors:
- 1 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (12) , 10041-10052
Abstract
Introduction ALK-rearranged lung adenocarcinomas with TP53 mutations have more unstable genomic features, poorer ALK-TKI efficacy and a worse prognosis than ALK-rearranged lung adenocarcinomas with wild-type TP53. Here, we examine the gene variations that co-occur with ALK/RET/ROS1 rearrangements in NSCLC and the corresponding tumor immune microenvironment, as well as their association with prognosis. Methods A total of 155 patients with ALK/RET/ROS1 fusions were included retrospectively. Tumor genome mutation analysis was performed by next-generation sequencing. PD-L1 expression and tumor-infiltrating lymphocytes were assessed by multiplex immunohistochemistry. The correlations among gene covariation, the tumor immune microenvironment, and clinicopathological characteristics were analyzed. Results Among the 155 patients, concomitant TP53 mutation appeared most frequently (31%), followed by CDKN2A/B copy number loss (15%). The ALK/RET/ROS1 fusion and TP53 or CDKN2A/B covariation group had more males and patients with stage IV disease (p < 0.001, p = 0.0066). Patients with TP53 or CDKN2A/B co-occurrence had higher tumor mutation burdens and more neoantigens (p < 0.001, p = 0.0032). PD-L1 expression was higher in the tumor areas of the TP53 or CDKN2A/B co-occurring group (p = 0.00038). However, the levels of CD8+, CD8+PD1−, and CD8+PD-L1− TILs were lower in the tumor areas of this group (p = 0.043, p = 0.029, p = 0.025). In the TCGA NSCLC cohorts, the top 2 mutated genes were CDKN2A/B (24%) and TP53 (16%). The TP53 or CDKN2A/B co-occurring group had higher tumor mutation burdens and shorter OS (p < 0.001, p < 0.001). Conclusions Patients with co-occurring TP53/CDKN2A/B variations and ALK/RET/ROS1 rearrangements are associated with high TMB, more neoantigens, an immunosuppressive microenvironment and a worse prognosis.Keywords
All Related Versions
Funding Information
- Zhongnan Hospital of Wuhan University Science, Technology, and Innovation Seed Fund (CXPY2019088, CXPY2019088, CXPY2019088)
This publication has 31 references indexed in Scilit:
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisClinical Cancer Research, 2016
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapyEuropean Journal of Cancer, 2016
- Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKILung Cancer, 2015
- EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3OncoImmunology, 2015
- Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung CancerClinical Cancer Research, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET FusionsThe Oncologist, 2013
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007